#5: CRISPR, Gene Editing, Access to Biotherapeutics & On-target approaches to the PhD journey (ft. Margareta Rybarikova)

Subscribe to the Global Health Conversations Newsletter to be updated on the latest interviews and episodes 🤩 :  https://globalhealthconversations.substack.com/?utm_source=substack&utm_medium=web&utm_campaign=substack_profileMargareta Rybarikova is a current PhD candidate with a keen interest in the development of novel therapies for genetic disorders. She received her Bachelor's degree in Biomedical Sciences from Brunel University London, where she focused on gene therapy, genomic medicine, molecular pharmacology, and cellular pathologies. Margareta went on to complete a Master's degree in Genes, Drugs, and Stem Cells - Novel Therapies at Imperial College London, where she was elected as the Course Representative. For her MSc project, she explored AAV-mediated gene editing with small Cas9 nucleases for Huntington's disease. Her passion for genetic therapy led her to pursue a PhD at the CHUV, as part of the Lemanic Neuroscience Doctoral School in Lausanne. In her doctoral research, she is developing a CRISPR-Cas9 system for ATXN3 gene editing in Spinocerebellar ataxia type 3 (SCA3).A friend of the podcast, Margareta discusses her research, gene therapies as a frontier in tackling rare diseases, access to biotherapeutics and balancing life and science and scientific career paths.Support the show